Microfluidic Affinity Profiling reveals a Broad Range of Target Affinities for Anti-SARS-CoV-2 Antibodies in Plasma of Covid Survivors
暂无分享,去创建一个
H. Fiegler | A. Aguzzi | D. Trono | V. Kosmoliaptsis | T. Knowles | Catherine K. Xu | B. M. Frey | P. Turelli | M. Emmenegger | G. Meisl | Itzel Condado Morales | Manuela R Zimmermann | Sebastian Fiedler | Viola Denninger | Matthias M. Schneider | Manuela R. Zimmermann | B. Frey
[1] C. Dobson,et al. Microfluidic Antibody Affinity Profiling for In-Solution Characterisation of Alloantibody - HLA Interactions in Human Serum , 2020 .
[2] Y. Pan,et al. Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients , 2020, Clinical Infectious Diseases.
[3] A. von Eckardstein,et al. Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region , 2020 .
[4] J. Jacobs. Neutralizing antibodies mediate virus-immune pathology of COVID-19 , 2020, Medical Hypotheses.
[5] F. Baldanti,et al. Plasma from donors recovered from the new Coronavirus 2019 as therapy for critical patients with COVID-19 (COVID-19 plasma study): a multicentre study protocol , 2020, Internal and Emergency Medicine.
[6] Jun Yuan,et al. Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.
[7] F. Lanza,et al. Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike , 2020, Transfusion and Apheresis Science.
[8] F. Lanza,et al. WITHDRAWN: Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: A rousing message of clinical benefit to both donors and recipients alike , 2020, Transfusion and Apheresis Science.
[9] Yongxiang Yi,et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19 , 2020, Aging.
[10] Holger Moch,et al. Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.
[11] Yan-ling Ma,et al. Antibody Detection and Dynamic Characteristics in Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Ioannidis,et al. COVID-19 antibody seroprevalence in Santa Clara County, California , 2020, medRxiv.
[13] Jennifer Abbasí. The Promise and Peril of Antibody Testing for COVID-19. , 2020, JAMA.
[14] Tianbing Wang,et al. Detection of antibodies against SARS‐CoV‐2 in patients with COVID‐19 , 2020, Journal of medical virology.
[15] Qi Jin,et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] Y. Yazdanpanah,et al. SARS-CoV-2 specific antibody responses in COVID-19 patients , 2020, medRxiv.
[17] Arturo Casadevall,et al. The convalescent sera option for containing COVID-19. , 2020, The Journal of clinical investigation.
[18] Yuan Shi,et al. Convalescent plasma as a potential therapy for COVID-19 , 2020, The Lancet Infectious Diseases.
[19] Jason A. Tetro,et al. Is COVID-19 receiving ADE from other coronaviruses? , 2020, Microbes and Infection.
[20] Daniel S. Chertow,et al. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design. , 2020, Cell host & microbe.
[21] C. Dobson,et al. Kinetic fingerprints differentiate anti-Aβ therapies , 2019 .
[22] C. Dobson,et al. Kinetic fingerprint of antibody therapies predicts outcomes of Alzheimer clinical trials , 2019, bioRxiv.
[23] B. Beutler. Innate immunity: an overview. , 2004, Molecular immunology.
[24] D. J. Harrison,et al. Monoclonal antibody binding affinity determined by microchip‐based capillary electrophoresis , 1998, Electrophoresis.
[25] R. Bertina,et al. Scatchard plot and heterogeneity in binding affinity of labeled and unlabeled ligand. , 1975, Clinical chemistry.